Levobeta C Retard

Carbidopa/Levodopa, the active ingredient in Levobeta C Retard, is a dopamine precursor and dopa decarboxylase inhibitor combination presented as an extended‑release oral tablet for oral administration. It is indicated for the management of Parkinson's disease and Parkinsonian syndrome, helping to improve motor function in adult patients.

GNH USA supplies Levobeta C Retard as a licensed, EU‑origin, GDP‑compliant international pharmaceutical product, providing reliable supply to hospitals, pharmacies and clinics worldwide. The product complies with European Union quality standards and is manufactured under GMP conditions to ensure consistency and safety for patients.

Carbidopa/Levodopa is used in the management of Parkinsonian disorders, targeting dopaminergic deficiency. - Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity, tremor and gait disturbances. - Parkinsonian syndrome: provides symptomatic relief of dopamine deficiency in secondary or atypical parkinsonism. - Secondary Parkinsonism: used when motor symptoms arise from drug‑induced or vascular causes, helping to restore movement control.

Carbidopa/Levodopa may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Orthostatic hypotension - Dizziness

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or psychosis - Severe hypotension leading to syncope

When prescribing Levobeta C Retard, clinicians should observe several safety measures. - Monitor for dyskinesia: assess for involuntary movements during therapy. - Evaluate cardiovascular status: watch for orthostatic hypotension and arrhythmias. - Review psychiatric history: be alert to hallucinations or mood changes. - Adjust dose in renal impairment: reduced clearance may increase exposure. - Avoid abrupt discontinuation: taper gradually to prevent withdrawal. - Store at room temperature: keep in original packaging, protect from moisture and light.

Carbidopa/Levodopa interacts with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis. - Selective MAO‑B inhibitors (e.g., selegiline) combined with levodopa: may cause severe hypertension. - Antipsychotics that block dopamine receptors (e.g., haloperidol): diminish therapeutic effect.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood pressure lowering. - SSRIs or SNRIs: potential for serotonin syndrome. - Iron or calcium supplements: may reduce levodopa absorption if taken simultaneously.